---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-073184"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2026-06-29T21:02:44+00:00"
generated_at: "2026-06-29T21:04:20.286533+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics CMO Leonardo Viana Nicacio resigns effective June 26, 2026

## Summary
- Leonardo Viana Nicacio, M.D., resigned as Chief Medical Officer to pursue other opportunities.
- Carla Beckham, M.D., Lead Medical Director and Head of Clinical Development, assumes his duties.
- Jacqueline Zummo, Ph.D., Chief R&D Officer, will oversee the clinical development function.
- Departure is effective June 26, 2026; no other officer changes disclosed.

## SEC filing metadata
- accession: 0001213900-26-073184
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2026-06-29T21:02:44+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390026073184/0001213900-26-073184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390026073184/ea0296286-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-073184
- JSON: https://secwatch.observer/filing/0001213900-26-073184.json
- Plain text: https://secwatch.observer/filing/0001213900-26-073184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.